<DOC>
	<DOC>NCT02038920</DOC>
	<brief_summary>This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002 (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or severely active Crohn's disease.</brief_summary>
	<brief_title>Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease</brief_title>
	<detailed_description>This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous Vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese patients with moderately or severely active Crohn's disease.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1. Patients aged 15 to 80 years (inclusive) at the time of consent 2. Patients with a diagnosis of smallintestinal, largeintestinal,or small/largeintestinal Crohn's disease established based on the Revised Diagnostic Criteria for Crohn's disease issued by Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2012) at least 3 months before the start of administration of study drug 3. Patients with baseline Crohn's Disease Activity Index (CDAI) score of 220 to 450(inclusive) and meeting at least one of the followings: Creactive protein (CRP) at screening test is above 0.30 mg/dL Patients with irregular or semicircular ulcers or multiple aphthae (10 or more) observed over an extensive area of the small or large intestine on endoscopy or imaging test within the 4 months before the start of administration of study drugs Patients with longitudinal ulcers or a cobblestone appearance observed in the small or large intestine on endoscopy or imaging test within 4 months before the start of administration of study drugs 4. In case of the patients who meet any of the following criteria; patients with ≥ 8year history of extensive or limited colitis, patients aged ≥ 50 years, or patients with a firstdegree family history of colon cancer, those whom the complication of colon cancer or dysplasia was ruled out by total colonoscopy at the start of study drug administration (Or the results from total colonoscopy performed within 1 year before giving consent are available) 5. Patients meeting the criteria for treatment failure below with at least one of the following agents received within previous 5 year period before giving consent Corticosteroids Resistance Dependence Intolerance Immunomodulators (azathioprine, 6mercaptopurine or methotrexate) Refractory Intolerance AntiTNFα antibodies Inadequate response Loss of response Intolerance Patients with an evidence of or suspected abdominal abscess 2. Patients with a history of subtotal or total colectomy 3. Patients who have had a resection of the small intestine in at least 3 locations or have a diagnosis of short bowel syndrome 4. Patients with ileostomy,colostomy,or internal fistula, or severe intestinal stenosis 5. Patients who started 5aminosalicylic acid oral drug or probiotics treatment, antimicrobials to treat Crohn's disease, or 30 mg/day or less of oral corticosteroids within 13 days before initiation of study drug administration. If these drugs were used within 14 days before initiation of study drug administration, the dosage must have been changed or their use discontinued within 13 days before the initiation of study drug administration 6. Patients who have received 5aminosalicylic acid or corticosteroid enemas/suppositories, intravenous corticosteroid injections, or more than 30 mg/day of oral corticosteroids, medications for diarrheapredominant irritable bowel syndrome, or Chinese herbal medicine for the treatment of Crohn's disease (e.g., Daikenchuto) within 13 days before initiation of study drug administration 7. Patients who have received azathioprine, 6mercaptopurine, or methotrexate within 27 days before initiation of study drug administration. However, this shall not apply to patients who have received these drugs for 83 or more days before initiation of the study drug administration and continued the steady dose administration of the drugs for 27 or more days before initiation of the study drug administration 8. Patients who have received cyclosporin, tacrolimus, tofacitinib or any study drugs for treatment of ulcerative colitis within 27 days before initiation of the study drug administration 9. Patients who have received adalimumab within 27 days before initiation of study drug administration or any biological drugs other than adalimumab within 55 days before initiation of study drug administration.Topical administration (such as intraocular implantation for treatment of agerelated maculopacy) is allowed 10. Patients who have received any live vaccinations within 27 days before initiation of study drug administration 11. Patients who have undergone intestinal resection within 27 days before initiation of study drug administration or those anticipated to require intestinal resection during the study 12. Patients who have received leukocytapheresis or granulocyte apheresis within 27 days before initiation of the study drug administration 13. Patients who have received intravenous hyperalimentation or total enteral nutrition within the 20 days before initiation of the study drug administration. Or patients who are fasted 14. Patients who have received enteral nutrition at &gt; 900 kcal/day or started enteral nutrition at &lt;= 900 kcal/day within the 20 days before initiation of the study drug administration. Patients receiving 900 kcal/day or less of enteral nutrition for at least 21 days before initiation of the study drug administration whom these dosage was changed or the medications were discontinued within 20 days before initiation of the study drug administration 15. Patients with evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration 16. Patients with a history or an an complication of dysplasia of the small or large intestine</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>